Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Is there a role for chemotherapy in nonmetastatic prostate cancer?
Daniel Keizman
, Mario Eisenberger
*
*
Corresponding author for this work
Johns Hopkins University
Bunting Blaustein Cancer Research Building
Research output
:
Contribution to journal
›
Article
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Is there a role for chemotherapy in nonmetastatic prostate cancer?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Chemotherapy
100%
Metastatic Prostate Cancer
100%
Natural History
50%
Patient Selection
50%
Distant Metastasis
50%
Clinical Trials
25%
Quality of Life
25%
Disease Survival
25%
Surrogate Endpoint
25%
Prospective Randomized Trial
25%
Clinical High Risk
25%
Standard of Care
25%
Parameter Identification
25%
Prognostic Biomarker
25%
Metastatic Disease
25%
Ongoing Clinical Trials
25%
Molecular Parameters
25%
Information for Patients
25%
Short-term Survival
25%
Pathological Parameters
25%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
25%
Patient Study
25%
Docetaxel Chemotherapy
25%
Clinical Trial Design
25%
Trial History
25%
Cancer Application
25%
Biomarker Endpoint
25%
Well Tolerated
25%
Non-metastatic Disease
25%
Medicine and Dentistry
Prostate Cancer
100%
Chemotherapy
100%
Clinical Trial
40%
Distant Metastasis
40%
Patient Selection
40%
Biological Marker
20%
Quality of Life
20%
Metastatic Carcinoma
20%
Docetaxel
20%
Castration Resistant Prostate Cancer
20%
Clinical Trial Design
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Chemotherapy Regimens
100%
Clinical Trial
40%
Distant Metastasis
40%
Biological Marker
20%
Castration Resistant Prostate Cancer
20%
Docetaxel
20%
Clinical Trial Design
20%
Diseases
20%